Our Therapeutic Areas

For more than 35 years, Gilead has discovered, developed and delivered innovative medicines in areas of great unmet medical need. Our ability to translate science into once-impossible advances has led to the commercialization of more than 29 life-changing therapies. Today, we have a robust portfolio and pipeline spanning virology, oncology and inflammation. We will continue relentlessly innovating in these therapeutic areas to transform care for people living with HIV, viral hepatitis, COVID-19, cancer, inflammatory diseases and other conditions.

Our History

Gilead was founded in 1987 with an initial focus on antiviral medicines. In 2001, we received our first approval for an HIV therapy, and in the years that followed we delivered many firsts in HIV management and prevention that have helped transform the trajectory of the disease. Using the same scientific approach, we were also able to deliver treatment options for hepatitis B, as well as four curative treatments for hepatitis C between 2013 and 2017.

Today, we’re using our deep knowledge of the human immune system to build on our legacy in virology and expand into other therapeutic areas. We’re developing novel potential new treatments for HIV and viral hepatitis, advancing an innovative oncology portfolio, helping respond to COVID-19 and other emerging viruses, and researching possible therapies for inflammatory and fibrotic diseases.

We will continue to invest in deepening our internal scientific expertise, collaborate with partners who help further our progress and keep the bar high as we bring forward new solutions to improve the lives of patients and the health of the world for generations to come.

Pursuing What’s Next

We continue to set bold ambitions in our pursuit of a healthier world for all people.

In 2019, we pledged to deliver 10+ transformative therapies over the next 10 years. Since then, we’ve been steadily growing our pipeline, our culture and our capabilities in our efforts to deliver on that goal and accelerate our progress toward our long-term ambitions in each therapeutic area.

We’re playing a key role in helping to end the HIV epidemic for everyone, everywhere. We’re working to eliminate HCV as a public health problem by 2030. In oncology, we have our sights set on delivering transformative therapies in more than 20 indications, impacting over 500,000 patient lives and becoming a top 10 oncology company by 2030. And we’re growing our inflammation portfolio with new approaches in chronic inflammation and fibrosis.

We know it will take more than medicine alone to combat these global health challenges. Beyond the science, we’re continuing to work with communities and partners around the world to improve healthcare access, eliminate the disparities and barriers to care encountered by underserved populations, and advance health equity that endures.